Arbor Biotechnologies: Unveiled FDA approval of an IND filing for their LNP-mediated treatment for primary hyperoxaluria type 1. Rothwell Figg (Dan Shores): Led a workshop on intellectual property challenges for LNP-based therapies at the LNP Summit. NOF CORPORATION: Presented biodegradable LNPs with tunable immunogenicity for vaccine and gene therapy applications. Serina Therapeutics: Introduced immune-silent POZ-lipid technology as a PEG alternative for LNPs at the

We are thrilled to announce that PreciGenome will be participating in the American Association for Cancer Research (AACR) Annual Meeting 202

Frontiers in Nanotechnology: Published research article on RNA-lipid nanoparticle therapeutics for women's health, focusing on gynecological